Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000-June 30, 2016

Godwin Oligbu, Sarah Collins, Abdelmajid Djennad, Carmen L. Sheppard, Norman Fry, Nicholas Andrews, Raymond Borrow, Mary Ramsay, Shamez Ladhani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

We describe the effects of the 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccines on pneumococcal meningitis in England and Wales during July 1, 2000-June 30, 2016. Overall, 84,473 laboratory-confirmed invasive pneumococcal disease cases, including 4,160 (4.9%) cases with meningitis, occurred. PCV7 implementation in 2006 did not lower overall pneumococcal meningitis incidence because of replacement with non-PCV7-type meningitis incidence. Replacement with PCV13 in 2010, however, led to a 48% reduction in pneumococcal meningitis incidence by 2015-16. The overall case-fatality rate was 17.5%: 10.7% among patients <5 years of age, 17.3% among patients 5-64 years of age, and 31.9% among patients ≥65 years of age. Serotype 8 was associated with increased odds of death (adjusted odds ratio 2.9, 95% CI 1.8-4.7). In England and Wales, an effect on pneumococcal meningitis was observed only after PCV13 implementation. Further studies are needed to assess pneumococcal meningitis caused by the replacing serotypes.

Original languageEnglish
Pages (from-to)1708-1718
Number of pages11
JournalEmerging Infectious Diseases
Volume25
Issue number9
DOIs
Publication statusPublished - 2019

Bibliographical note

Publisher Copyright:
© 2019 Centers for Disease Control and Prevention (CDC). All rights reserved.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Fingerprint

Dive into the research topics of 'Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000-June 30, 2016'. Together they form a unique fingerprint.

Cite this